HighTower Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$93.8M Sell
475,948
-6,676
-1% -$1.29M 0.1% 204
2025
Q4
$88.7M Buy
482,624
+3,506
+0.7% +$615K 0.1% 214
2025
Q3
$73.5M Buy
479,118
+15,979
+3% +$2.42M 0.08% 243
2025
Q2
$64.7M Buy
463,139
+90,340
+24% +$12.7M 0.08% 258
2025
Q1
$54.8M Buy
372,799
+17,486
+5% +$2.53M 0.07% 275
2024
Q4
$46.6M Sell
355,313
-8,020
-2% -$1.12M 0.06% 299
2024
Q3
$56.6M Sell
363,333
-3,677
-1% -$594K 0.08% 251
2024
Q2
$57.2M Buy
367,010
+16,817
+5% +$2.53M 0.09% 237
2024
Q1
$47.4M Buy
350,193
+13,551
+4% +$1.79M 0.08% 262
2023
Q4
$45.3M Buy
336,642
+9,720
+3% +$1.26M 0.08% 262
2023
Q3
$44.3M Buy
326,922
+189,301
+138% +$25.9M 0.08% 238
2023
Q2
$19.7M Buy
137,621
+24,409
+22% +$3.59M 0.04% 435
2023
Q1
$15.7M Buy
113,212
+9,711
+9% +$1.31M 0.03% 479
2022
Q4
$14M Sell
103,501
-4,441
-4% -$557K 0.03% 502
2022
Q3
$11.9M Buy
107,942
+13,300
+14% +$1.69M 0.03% 505
2022
Q2
$12.5M Buy
94,642
+24,963
+36% +$3.28M 0.03% 493
2022
Q1
$9.25M Sell
69,679
-31,695
-31% -$3.8M 0.02% 653
2021
Q4
$11.8M Buy
101,374
+3,041
+3% +$358K 0.03% 542
2021
Q3
$11.8M Buy
98,333
+18,423
+23% +$2.14M 0.03% 479
2021
Q2
$9.58M Buy
79,910
+18,820
+31% +$2.06M 0.03% 534
2021
Q1
$6.01M Buy
61,090
+9,109
+18% +$916K 0.02% 677
2020
Q4
$5.15M Buy
51,981
+13,065
+34% +$1.38M 0.02% 582
2020
Q3
$4.25M Buy
38,916
+13,367
+52% +$1.49M 0.02% 608
2020
Q2
$2.7M Sell
25,549
-671
-3% -$69.3K 0.01% 704
2020
Q1
$2.34M Buy
+26,220
New +$2.47M 0.02% 701
2019
Q4
Sell
-28,339
Closed -$2.52M 2351
2019
Q3
$2.52M Buy
28,339
+3,701
+15% +$321K 0.01% 813
2019
Q2
$2.03M Sell
24,638
-1,787
-7% -$140K 0.01% 894
2019
Q1
$2.13M Sell
26,425
-2,376
-8% -$187K 0.01% 830
2018
Q4
$2.19M Sell
28,801
-746
-3% -$58.3K 0.02% 731
2018
Q3
$2.35M Sell
29,547
-29,335
-50% -$2.22M 0.02% 782
2018
Q2
$4.14M Sell
58,882
-3,106
-5% -$223K 0.03% 556
2018
Q1
$4.33M Sell
61,988
-3,971
-6% -$275K 0.04% 514
2017
Q4
$4.57M Sell
65,959
-7,218
-10% -$487K 0.04% 503
2017
Q3
$4.96M Buy
73,177
+4,963
+7% +$314K 0.04% 464
2017
Q2
$4.64M Sell
68,214
-25,521
-27% -$1.67M 0.04% 490
2017
Q1
$5.83M Sell
93,735
-4,227
-4% -$246K 0.06% 380
2016
Q4
$5.35M Sell
97,962
-52,772
-35% -$3M 0.06% 367
2016
Q3
$9.91M Sell
150,734
-10,890
-7% -$712K 0.11% 179
2016
Q2
$9.76M Sell
161,624
-114,028
-41% -$6.62M 0.12% 173
2016
Q1
$15.5M Buy
275,652
+11,501
+4% +$691K 0.05% 137
2015
Q4
$17.9M Sell
264,151
-129,318
-33% -$8.48M 0.21% 106
2015
Q3
$25.1M Buy
+393,469
New +$25.9M 0.33% 63
2015
Q2
Sell
-321,172
Closed -$22M 1560
2015
Q1
$22M Buy
321,172
+48,854
+18% +$3.39M 0.33% 62
2014
Q4
$19.2M Buy
272,318
+130,721
+92% +$9.36M 0.29% 75
2014
Q3
$10.1M Sell
141,597
-25,514
-15% -$1.87M 0.17% 136
2014
Q2
$12.4M Buy
167,111
+155,133
+1,295% +$11.2M 0.22% 101
2014
Q1
$777K Sell
11,978
-3,118
-21% -$201K 0.02% 824
2013
Q4
$896K Sell
15,096
-87,049
-85% -$4.73M 0.02% 743
2013
Q3
$5.32M Buy
102,145
+8,589
+9% +$431K 0.13% 182
2013
Q2
$4.42M Buy
+93,556
New +$4.76M 0.12% 194

Other funds holding AZN

HighTower Advisors's AZN Position: Q1 2026 in Review

HighTower Advisors reduced its AstraZeneca (AZN) stake by 1.4% in Q1 2026, selling an estimated $1.29M and leaving 475,948 shares worth $93.8M. The position accounts for 0.1% of the portfolio, ranked #204.

HighTower Advisors first reported a position in AZN in Q2 2013 and has held it in 50 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • HighTower Advisors held 475,948 shares of AstraZeneca worth $93.8M as of Q1 2026.
  • HighTower Advisors sold 6,676 AstraZeneca shares in Q1 2026, an estimated $1.29M.
  • AstraZeneca made up 0.1% of HighTower Advisors's portfolio in Q1 2026, its #204 holding.
  • HighTower Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 50 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.